📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
18 analysed today
FollowTelegram
18
Today
151,880
All-time analysed
43,545
Positive
6,744
Negative
92,753
Neutral
8,770
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
846 announcements match the current filters (relevance ≥ 5).
Bhartiya International Incorporates New Step-Down Subsidiary ULTIMA FASHIONS UK LTD in UK
Bhartiya International Limited (BIL) has announced the successful incorporation of a new step-down subsidiary in the United Kingdom. The new entity, named ULTIMA FASHIONS UK LTD, was incorporated on January 16, 2026. It is a wholly owned subsidiary of Ultima SA, which is an existing subsidiary of BIL. This move follows the company's initial proposal disclosed on January 15, 2026, and signifies a strategic push to expand its footprint in the UK market.
Key Highlights
Incorporation of ULTIMA FASHIONS UK LTD as a wholly owned subsidiary of Ultima SA.
The new entity was officially registered in the United Kingdom on January 16, 2026.
Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.
Strategic expansion of the company's international fashion business operations.
👀 What to Watch
Investors should monitor the company's future updates regarding the scale of operations and capital investment in this new UK unit. This expansion could lead to better revenue diversification in the long term.
Bhartiya International to Incorporate UK Step-Down Subsidiary with GBP 50,000 Investment
Bhartiya International Limited (BIL) has announced the incorporation of a new step-down wholly owned subsidiary in the United Kingdom through its subsidiary, Ultima SA. The new entity will focus on the Textile and Apparel business to support the company's operations in the UK market. The initial investment is capped at GBP 50,000, comprising 5,000 ordinary shares at a face value of GBP 10 each. This move indicates a strategic push to strengthen the company's direct presence in the European region.
Key Highlights
Incorporation of a 100% step-down wholly owned subsidiary in the United Kingdom.
Initial investment not exceeding GBP 50,000 divided into 5,000 ordinary shares.
The entity will operate in the Textile and Apparel sector to support UK business operations.
The expansion is being executed through Ultima SA, an existing wholly owned subsidiary of BIL.
👀 What to Watch
Investors should view this as a positive step toward international market consolidation, though the small initial investment suggests a lean operational start. Monitor future revenue contributions from the UK segment to gauge the success of this expansion.
Biocon Completes Rs 4,150 Crore QIP to Fully Acquire Biocon Biologics Stake
Biocon Limited has successfully raised Rs 4,150 crore (~USD 460 million) through a Qualified Institutions Placement (QIP) by issuing 11.26 crore shares at Rs 368.35 per share. The primary purpose of this fundraise is to finance the buyout of Viatris' (Mylan Inc.) stake in Biocon Biologics and to repay debt associated with this acquisition and Edelweiss CCDs. This strategic move will make Biocon Biologics a 100% wholly owned subsidiary by March 31, 2026. The QIP attracted 39 institutional investors, including major names like SBI Mutual Fund, ICICI Prudential, and JPMorgan.
Key Highlights
Raised Rs 4,150 crore through the issuance of 112,664,585 equity shares at Rs 368.35 each.
Funds will be used to acquire the remaining minority stake in Biocon Biologics from Viatris.
Aims to repay debt incurred for the acquisition of Biocon Biologics shares and Edelweiss CCDs.
The integration of Biocon Biologics as a wholly owned subsidiary is expected by March 31, 2026.
Strong institutional participation from 39 domestic and international investors.
👀 What to Watch
The successful fundraise and move to 100% ownership of the biologics business is a significant positive for long-term value unlocking. Investors should monitor the impact of debt reduction and the operational integration of the biologics unit on future earnings.
Biocon Allots 11.27 Crore Equity Shares via QIP to Raise ₹4,150 Crore
Biocon Limited has successfully completed a Qualified Institutional Placement (QIP), raising ₹41,500 million (₹4,150 crore) to strengthen its financial position. The company allotted 11,26,64,585 equity shares at an issue price of ₹368.35 per share, representing a significant capital infusion. Major institutional investors including SBI Mutual Fund and ICICI Prudential Mutual Fund participated heavily, each taking up nearly 29.5% of the total issue. This fundraise results in an equity dilution of approximately 7.47% as the total share count increases to 162.09 crore shares.
Key Highlights
Allotted 11,26,64,585 equity shares at an issue price of ₹368.35 per share
Total capital raised through the QIP amounts to ₹41,500 million (₹4,150 crore)
Paid-up equity capital increased from ₹754.12 crore to ₹810.45 crore
SBI Mutual Fund and ICICI Prudential Mutual Fund emerged as lead allottees, each securing 29.5% of the issue
The placement was completed within a two-day window from January 12 to January 14, 2026
👀 What to Watch
Investors should factor in the ~7.5% equity dilution on future EPS while noting the strong institutional backing and improved liquidity for the company. Monitor management commentary regarding the specific utilization of these funds, likely for debt reduction or biosimilar growth initiatives.
Biocon completes ₹4,150 Cr QIP; allots 11.26 Cr shares at ₹368.35 per share
Biocon Limited has successfully concluded its Qualified Institutions Placement (QIP) on January 14, 2026, raising approximately ₹4,150 crore. The company approved the allocation of 11,26,64,585 equity shares to institutional investors at a final price of ₹368.35 per share. This issue price represents a 5% discount to the regulatory floor price of ₹387.74. The successful closure and institutional participation indicate strong market confidence in the company's growth prospects.
Key Highlights
Allocated 11,26,64,585 equity shares of face value ₹5 each to qualified institutional buyers.
Issue price fixed at ₹368.35 per share, which includes a premium of ₹363.35.
The final issue price reflects a 5% discount (₹19.39) to the floor price of ₹387.74.
The total fundraise amount is approximately ₹4,150 crore based on the allotted shares and price.
The QIP was opened on January 12, 2026, and closed on January 14, 2026.
👀 What to Watch
Investors should view this as a positive liquidity event that strengthens the balance sheet, though they should account for the resulting equity dilution. Monitor management's commentary on the specific utilization of these funds for debt reduction or expansion.
Biocon Closes QIP Raising Approx ₹4,150 Crore at ₹368.35 Per Share
Biocon Limited has successfully concluded its Qualified Institutions Placement (QIP) which opened on January 12, 2026. The company's Fund Raising Committee approved the allocation of 11,26,64,585 equity shares to eligible institutional buyers. The issue price was finalized at ₹368.35 per share, representing a total fundraise of approximately ₹4,150 crore. This capital infusion is expected to strengthen the company's balance sheet and support its strategic growth initiatives.
Key Highlights
Allocation of 11,26,64,585 equity shares of face value ₹5 each to qualified institutional buyers.
Issue price fixed at ₹368.35 per share, which includes a premium of ₹363.35.
The final price represents a 5% discount to the regulatory floor price of ₹387.74 per share.
The fundraise was completed within a three-day window from January 12 to January 14, 2026.
👀 What to Watch
Investors should view this as a positive step for capital adequacy, though they should account for the equity dilution. Monitor management's commentary on the specific utilization of these funds, particularly regarding debt reduction in the biosimilars segment.
Biocon Completes ₹4,150 Crore QIP; Allocates 11.26 Crore Shares at ₹368.35
Biocon Limited has successfully closed its Qualified Institutions Placement (QIP) on January 14, 2026. The company approved the allocation of 11,26,64,585 equity shares to qualified institutional buyers at an issue price of ₹368.35 per share. This price represents a 5% discount to the floor price of ₹387.74 per share. The total capital raised through this issue is approximately ₹4,150 crore, which will likely be used to strengthen the balance sheet or fund expansion.
Key Highlights
Allocated 11,26,64,585 equity shares of face value ₹5 each to eligible QIBs
Issue price fixed at ₹368.35 per share, including a premium of ₹363.35
Applied a 5% discount to the floor price of ₹387.74 as per SEBI regulations
Total fundraise amount estimated at approximately ₹4,150 crore
Issue was opened on January 12, 2026, and closed on January 14, 2026
👀 What to Watch
Investors should view this as a positive liquidity event that strengthens Biocon's capital structure, though they should account for the equity dilution in future EPS estimates. Monitor the company's specific plans for fund deployment, particularly regarding debt reduction or biosimilar pipeline development.
Aditya Birla Money Q3 PAT at ₹14.22 Cr; Revenue Up 12% QoQ to ₹119.58 Cr
Aditya Birla Money reported a sequential recovery in Q3 FY26 with a Profit After Tax (PAT) of ₹14.22 crore, up 40% from the previous quarter, though it remains 35% lower than the ₹21.81 crore reported in the same quarter last year. Revenue from operations grew 12.3% QoQ to ₹119.58 crore, driven by growth in both Broking and Wholesale Debt Market segments. The company recognized an exceptional charge of ₹3.13 crore due to the implementation of new Labour Codes. Despite the QoQ improvement, operating margins contracted significantly to 15.24% compared to 28.73% in the year-ago period.
Key Highlights
Revenue from operations increased 11.5% YoY and 12.3% QoQ to ₹119.58 crore.
Net Profit (PAT) stood at ₹14.22 crore, showing 40.2% growth over Q2 FY26 but a 34.8% decline YoY.
Broking segment revenue grew to ₹92.13 crore, while Wholesale Debt Market revenue rose to ₹26.71 crore.
Operating margins declined to 15.24% from 28.73% in the previous year's corresponding quarter.
An exceptional item of ₹3.13 crore was recorded for statutory impacts related to new Labour Codes.
👀 What to Watch
Investors should monitor the margin compression and the impact of the new labor codes on long-term employee costs. While sequential growth is positive, the year-on-year decline in profitability suggests rising competitive pressures.
Rubicon Research Expands to Saudi Arabia with New Subsidiary AdvaGen S A
Rubicon Research Limited has successfully incorporated a wholly owned subsidiary, AdvaGen S A Company, in the Kingdom of Saudi Arabia as of January 13, 2026. The new entity is established with an initial share capital of SAR 1,00,000, consisting of 100 equity shares at a face value of SAR 1,000 each. This move marks the company's strategic entry into the Saudi Arabian pharmaceutical market to deal in various pharma products. The investment is a 100% cash consideration, ensuring full control by Rubicon Research.
Key Highlights
Incorporation of AdvaGen S A Company in Saudi Arabia as a 100% wholly owned subsidiary
Initial subscription cost of SAR 1,00,000 for 100 equity shares
The subsidiary will focus on the pharmaceutical industry and product dealing
Strategic geographic expansion into the Middle Eastern healthcare market
No governmental or regulatory approvals were required for the incorporation
👀 What to Watch
Investors should view this as a positive step toward geographic diversification and market expansion. Monitor the subsidiary's future performance and its ability to scale operations in the GCC region.
A B Infrabuild Secures ₹55.26 Crore Railway Project from East Coast Railways
A B Infrabuild Limited has been awarded a domestic contract worth approximately ₹55.26 crore by East Coast Railways. The project involves the construction of a Road Over Bridge (ROB) in the Khurda Road Division, specifically between Jhadupudi and Sompeta Railway stations. The company is expected to complete the project within a 24-month timeframe. This new order strengthens the company's infrastructure portfolio and provides revenue visibility for the next two fiscal years.
Key Highlights
Total contract value is ₹55,26,31,365.74 (approx. ₹55.26 Crores)
Project awarded by East Coast Railways, Indian Railways, for construction of a Road Over Bridge
Execution timeline for the project is 24 months
Project includes construction of composite and RCCT-Beam girders at Rly. Km. 641/19-21
👀 What to Watch
Investors should view this as a positive development that bolsters the order book; focus on the company's ability to maintain margins during the 24-month execution period.
Biocon Approves Interim Financial Statements for H1 FY26 Amid QIP Process
Biocon Limited has released its unaudited condensed consolidated interim financial statements for the six-month period ended September 30, 2025. This disclosure is a procedural requirement following the company's announcement regarding a Qualified Institutions Placement (QIP). The statements provide a comparative analysis against the same period in 2024 and have been reviewed by statutory auditors M/s. B S R & Co. LLP. This filing ensures financial transparency for institutional investors participating in the upcoming fundraise.
Key Highlights
Approval of unaudited condensed consolidated interim financial statements for the half-year ended September 30, 2025.
Financials include comparative data for the six-month period ended September 30, 2024.
Statements prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013.
Limited review report issued by statutory auditors M/s. B S R & Co. LLP.
Filing supports the ongoing Qualified Institutions Placement (QIP) issue opening.
👀 What to Watch
Investors should monitor the pricing and size of the QIP as these interim financials provide the basis for institutional valuation. No immediate action is required other than tracking potential equity dilution from the fundraise.
Biocon Subsidiary Receives US FDA Approval for Everolimus Tablets (2mg, 3mg, 5mg)
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received US FDA approval for its ANDA for Everolimus Tablets for Oral Suspension. The approval covers three dosage strengths: 2 mg, 3 mg, and 5 mg, targeting the treatment of Tuberous Sclerosis Complex (TSC). This product is indicated for both adult and pediatric patients, specifically for those with Subependymal Giant Cell Astrocytoma or TSC-associated seizures. This regulatory milestone strengthens Biocon's vertically integrated drug portfolio in the critical US market.
Key Highlights
Received US FDA approval for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths.
Indicated for TSC patients with SEGA (aged 1+) and TSC-associated partial-onset seizures (aged 2+).
Approval granted to Biocon Pharma Limited, a 100% subsidiary of Biocon Limited.
Strengthens the company's portfolio of vertically integrated drug products for international markets.
👀 What to Watch
Investors should monitor the commercial launch timeline and the potential market share Biocon can capture in this niche segment. This approval validates Biocon's R&D capabilities and supports long-term growth in its generics business.
BirlaNu Wins GST Case: Telangana HC Rescinds ₹16.76 Crore Tax and Penalty Demand
BirlaNu Limited (formerly HIL Limited) has received a favourable ruling from the Telangana High Court regarding a long-standing GST dispute. The court rescinded a proposed tax demand of ₹8.38 crore and an equivalent penalty of ₹8.38 crore related to Input Service Distributor (ISD) registration. This order effectively eliminates a total potential liability of approximately ₹16.76 crore. The company confirmed that no tax, interest, or penalty is now payable in this specific matter, strengthening its financial position.
Key Highlights
Telangana High Court rescinded a GST demand of ₹8.38 crore
A penalty of ₹8.38 crore previously proposed has been entirely dropped
Total financial relief for the company amounts to approximately ₹16.76 crore
The dispute originated from the company's Input Service Distributor (ISD) registration methodology
The order was received on January 7, 2026, following a decision dated December 30, 2025
👀 What to Watch
This is a positive outcome that clears a potential financial liability from the company's books. Investors should view this as a resolution of legal risk, though it does not fundamentally change the core business operations.
A B Infrabuild Secures ₹54.26 Crore Railway Project from East Coast Railways
A B Infrabuild Limited has secured a new contract from East Coast Railways for the construction of a Road Over Bridge (ROB) on the HWH-VSKP Main Line. The project, valued at approximately ₹54.26 Crore, involves the construction of composite and T-beam girders. This domestic order is scheduled for completion within a 24-month period. The win reinforces the company's presence in the railway infrastructure segment.
Key Highlights
Awarded a ₹54.26 Crore contract by East Coast Railways for bridge construction.
Project involves building a Road Over Bridge (ROB) with composite and T-beam girders.
Execution timeline for the project is 24 months from the date of acceptance.
The contract is located in the Khurdha Road Division on the HWH-VSKP Main Line.
👀 What to Watch
Investors should view this as a positive development for the company's order book and future revenue visibility. Monitor the execution progress over the 24-month timeline to ensure margins are maintained.
Panacea Biotec Completes Phase III Enrollment for DengiAll Vaccine with 10,335 Participants
Panacea Biotec has achieved a major milestone by completing the enrollment of 10,335 participants for the Phase III clinical trials of DengiAll, India's first indigenous single-shot dengue vaccine. The trial, conducted in collaboration with ICMR, will now move into a two-year monitoring phase to evaluate the vaccine's efficacy and immunogenicity. This development keeps the company on track for a projected market entry by 2027. Successful commercialization would address a significant unmet medical need in tropical regions, potentially creating a substantial long-term revenue stream.
Key Highlights
Completed enrollment of 10,335 study participants for Phase III clinical trials of DengiAll vaccine.
DengiAll is positioned as India's first indigenous single-shot tetravalent dengue vaccine candidate.
Two-year monitoring period initiated to examine long-term efficacy and immunogenicity post-administration.
Commercial market launch is anticipated by 2027 following the completion of the observation period.
Project is being executed in collaboration with the Indian Council of Medical Research (ICMR).
👀 What to Watch
Investors should maintain a positive outlook on the company's R&D pipeline as this milestone reduces execution risk. However, since commercialization is expected only by 2027, this remains a long-term play with interim clinical data being the next key catalyst.
Biocon to Expand Oncology Portfolio with Keytruda & Opdivo Biosimilars; Integration by March 2026
Biocon Biologics is expanding its oncology portfolio with three major biosimilars targeting drugs with combined 2024 sales exceeding $40 billion, including Keytruda and Opdivo. The company is on track to integrate Biocon Biologics as a wholly owned subsidiary by March 31, 2026, to streamline operations and focus on high-growth areas like GLP-1 peptides and insulins. This strategic move targets a $75 billion oncology market opportunity, representing 35% of the global pharmaceutical market. Post-integration, Shreehas Tambe will lead the combined entity as CEO & Managing Director.
Key Highlights
Unveiling biosimilars for Keytruda ($29.5B sales), Opdivo ($9.3B), and Herceptin SC ($1.72B)
Oncology portfolio now includes 17 assets, targeting an addressable market of over $75 billion
Full integration of Biocon Biologics into Biocon Ltd expected to be completed by March 31, 2026
Strategic focus on Diabetes, Oncology, and Immunology, which comprise 40% of global pharma revenue
👀 What to Watch
Investors should monitor the progress of the corporate integration and the regulatory filing timelines for the high-value oncology biosimilars. The combined focus on GLP-1 peptides and biosimilar insulins positions the company well for the growing global metabolic health market.
A B Infrabuild Secures Rs 10.75 Crore EPC Road Project in Madhya Pradesh
A B Infrabuild Limited has been awarded a new contract by the M.P. Road Development Corporation Ltd for road infrastructure work. The project involves constructing additional lanes for truck parking and lay byes on the NH-30 stretch in Madhya Pradesh. Valued at Rs 10.75 crore, the contract will be executed on an EPC (Engineering, Procurement, and Construction) basis. The project is expected to be completed within a short timeframe of 9 months, which could lead to rapid revenue recognition.
Key Highlights
New project award worth Rs 10.75 crore from M.P. Road Development Corporation Ltd.
Project involves construction of truck parking lanes on the Mangawan to MP-UP border section of NH-30.
Execution timeline is set at 9 months, indicating a fast-track project cycle.
The contract is awarded on an EPC mode, ensuring the company handles design and construction.
No promoter or group company interest involved, ensuring a standard commercial transaction.
👀 What to Watch
Investors should view this as a positive addition to the company's order book, providing revenue visibility for the next three quarters. Monitor the company's ability to execute within the 9-month deadline to maintain margins.
ABINFRA Secures Rs 10.75 Crore EPC Contract for NH-30 Project in Madhya Pradesh
A B Infrabuild Limited has been awarded a new domestic contract worth Rs 10.75 crore by the M.P. Road Development Corporation Ltd. The project involves the construction of additional lanes for truck parking and lay byes on the Sohagi Ghat stretch of NH-30. This project will be executed under the EPC (Engineering, Procurement, and Construction) mode. The company is expected to complete the project within a relatively short timeframe of 9 months.
Key Highlights
Total contract value is Rs 10.75 crore (Ten Crore Seventy-Five Lakh Only).
Project awarded by M.P. Road Development Corporation Ltd for work on NH-30.
Execution timeline is set for 9 months from the date of commencement.
The contract is for the construction of truck parking/lay byes in the Sohagi Ghat stretch.
The project is a domestic order and involves no related party transactions.
👀 What to Watch
Investors should view this as a positive development for the company's order book, though the contract size is moderate. Monitor the company's ability to execute within the 9-month deadline to ensure timely revenue realization.
Biocon Consolidates Biocon Biologics Stake to 94% via Share Swap and USD 200M Cash
Biocon Limited has significantly increased its ownership in its subsidiary, Biocon Biologics Limited (BBL), to approximately 94% on a fully diluted basis. The transaction involved acquiring 26.19 crore BBL shares through a share swap, issuing 17.12 crore new Biocon shares at Rs. 405.78 each to partners including Mylan and Serum Institute. Additionally, the company completed a cash acquisition of 7.18 crore BBL shares from Mylan for USD 200 million. While this consolidates a high-growth asset, it results in an 11.36% equity dilution for existing Biocon shareholders.
Key Highlights
Acquired 33.37 crore total shares of Biocon Biologics, taking ownership to ~94% on a fully diluted basis
Issued 17.12 crore new equity shares at a preferential price of Rs. 405.78 per share
Paid USD 200 million in cash to Mylan as part of a larger USD 400 million acquisition agreement
Post-allotment, Mylan Inc. and Serum Institute hold 6.10% and 3.68% stakes in Biocon Ltd respectively
Total paid-up equity capital increased from 133.69 crore shares to 150.82 crore shares
👀 What to Watch
Investors should view the consolidation of the biologics arm as a strategic positive for long-term valuation, though they must factor in the 11% equity dilution. Monitor the company's debt profile following the USD 200 million cash payout.
Biocon Allots 17.13 Cr Shares to Consolidate Biocon Biologics Stake; Holding Reaches 94%
Biocon Limited has completed a significant consolidation of its subsidiary, Biocon Biologics Limited (BBL), by acquiring shares from Mylan, Serum Institute, and other partners. The company allotted 17.13 crore equity shares at an issue price of Rs. 405.78 per share, resulting in an 11.36% equity dilution. Additionally, Biocon paid USD 200 million in cash to Mylan for a portion of the stake. Following these transactions, Biocon's ownership in its high-growth biologics arm has increased to approximately 94% on a fully diluted basis.
Key Highlights
Allotted 17,12,79,553 equity shares at Rs. 405.78 per share on a preferential basis.
Acquired 26.19 crore BBL shares via share swap and 7.18 crore BBL shares for USD 200 million cash.
Biocon's total holding in Biocon Biologics Limited (BBL) increased to approximately 94%.
Post-allotment, Mylan Inc. holds 6.10% and Serum Institute holds 3.68% in Biocon Limited.
Total paid-up equity share capital increased from 133.70 crore to 150.82 crore shares.
👀 What to Watch
Investors should note the consolidation of the biologics business as a long-term positive for control and simplified structure, though they must account for the 11.36% equity dilution. Monitor the performance of Biocon Biologics as it now represents a much larger portion of the parent's value.
